Therapeutic Antibodies in Inflammatory Diseases

Trade name INN Technology mAb isotype Target Indication Route Dose Schedule 

Humira Adalimumab Human (Phage display) IgGi TNF-a RA SC 40 mg Biweekly 

Orthoclone-OKT3 Muromonab-CD3 Murine IgG2a CD3 Organ Transplant IV 5 mg Daily (10-14 days) 

Remicade Infliximab Chimeric IgGi TNF-a RA, Crohn s disease IV 3-10 mg/kg Biweekly-bimonthly 

Raptiva Efalizumab Humanized IgGi CDlla Plaque psoriasis sc 1 mg/kg Weekly 

---